AI is changing drug discovery

Drug discovery is getting a much-needed charge from a surprising source: artificial intelligence. Scientists are applying AI in new ways to guide and accelerate drug discovery, and this has life sciences investors on the edge of our seats.

Traditional drug discovery is a grind. For decades, the process was primarily manual and required a lot of highly skilled people conducting research and spending a long time analyzing data sets and coming up with models. Drugs take several years to get to trial, and the cost of developing a single drug from discovery to commercial launch can be up to $12 billion over 10 years.

Using AI, scientists can process much more data, run more scenarios, and zero in on the best compounds far more quickly and efficiently than any team of humans. In fact, AI has the potential to trim that timeline down to a year or even months, which subsequently brings down costs. As researchers around the world hurry to discover a vaccine or treatment for Covid-19, artificial intelligence may prove an indispensable tool that helps scientists process data and make connections at a pace we’ve never seen before.

The life sciences industry is hungry for inventors to introduce new technologies that will shape the future of medicine, and I believe innovation in these three areas will make healthcare safer, cheaper, and more effective for patients and more sustainable for the world. That’s a future worth investing in.

Originally published at https://www.linkedin.com.

Co-Founder and Managing Partner at Biospring Partners https://www.biospring.com | https://michelle-dipp.com